Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia
NCT06771323Phase 2Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valbenazine in cervical dystonia (CD) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale-2 Motor Severity score change at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
valbenazine
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT06771323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771323.